BETHESDA, MD November 7, 2008 Thousands of the world's top scientists and clinicians in the human genetics field will convene to present their latest research at the 58th Annual Meeting of The American Society of Human Genetics (ASHG) in Philadelphia, Pennsylvania on November 11-15, 2008.
A number of scientific presentations at the ASHG 2008 Annual Meeting will provide information about important new research findings that advance our current understanding of possible causes of genetic conditions. A number of these studies go a step further in their quest to translate knowledge gained from scientific research into novel genetic therapies that can be used to treat patients in clinical practice.
ASHG will host a press briefing session to highlight four of the top research presentations at the 2008 Annual Meeting that report findings on important breakthroughs in the successful treatment of disease through novel genetic therapies and treatments, and the management of health conditions through findings from pharmacogenetics research.
ASHG invites members of the media to attend this press briefing session on "Novel Genetic Disease Treatments and Therapies: From Scientific Discovery to Medical Delivery," which will be held on Friday, November 14, 2008 from 11:15 a.m. to 12:15 p.m. in the ASHG Press Briefing Room (Room 307A), located on the third floor of the Pennsylvania Convention Center. This session will feature exciting new scientific research on successful genetic disease treatments and therapies, as well as new pharmacogenetics research findings that provide insights into appropriate drug dosage based on genetic variants.
The presentations included in this press briefing will report on: the results of a genome-wide association scan for genetic determinants of warfarin dosage, breakthrough research on a new treatment that has the potential to be the first successful therapy for Huntington's Disease, a long-term study on
|Contact: Kristen Long|
American Society of Human Genetics